Formulated for glaucoma to manage ocular pressure and support vision maintenance.
Mechanism of Action
This topical agent inhibits carbonic anhydrase II in the ciliary processes of the eye. By decreasing bicarbonate ion secretion, it reduces aqueous humor production and subsequently lowers intraocular pressure.
Route of Administration
Ophthalmic
Onset Time
2 hours
Duration
8–12 hours
Contraindications
Hypersensitivity to sulfonamides, Severe renal impairment, Hypersensitivity to dorzolamide
Severe Adverse Events
Corneal edema, Anaphylaxis, Stevens-johnson syndrome — requires immediate medical attention
Common Side Effects
Burning, Stinging, Bitter taste
Uncommon Side Effects
Blurred vision, Eye redness, Tearing
Drug Interactions
Alcohol, Acetazolamide, Aspirin
Pregnancy Safety Warnings
FDA Category C: Use only if clearly needed. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy established in pediatric patients for glaucoma.
Information related to Trusopt is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
